INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) Files An 8-K Other Events
Item8.01. Other Events.
On April13, 2017, Intellia Therapeutics,Inc. (the Company) issued
a press release entitled CRISPR Therapeutics, Intellia
Therapeutics, Caribou Biosciences and ERS Genomics Announce
Appeal of CRISPR/Cas9 U.S. Patent Board Decision. A copy of the
press release is filed herewith as Exhibit99.1 and is
incorporated into this Item8.01 by reference.
Item9.01. Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit Number |
Description |
|
| 99.1 |
Press release dated April 13, 2017, entitled CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision |
***
About INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA)
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue. INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) Recent Trading Information
INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) closed its last trading session down -0.37 at 13.48 with 96,287 shares trading hands.
